The US Food and Drug Administration is suggesting drug formulation options intended to inhibit the development of potentially carcinogenic nitrosamines, a problem first found in OTC heartburn remedies containing ranitidine.
The options, called “mitigation strategies” in an update the agency published on 22 November, include adding antioxidants such as vitamin...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?